Abstract: This invention provides for a method of improving chemotherapeutic, targeted therapy or immunotherapeutic treatments for cancers arising from oncogene activity. The method provides for the combination of a COT inhibitor with a therapeutic specific for the oncogene. Methods of diagnosing the status of the patients, who are predisposed to benefit from this combination therapy are also described here. The use of any COT inhibitor in combination with other drugs for the treatment of cancer patients expressing COT. COT expression serves as a way for several oncogenes to stimulate proliferation or anti-apoptotic signaling that compromises drugs clinical benefit. To avoid that reduced clinical benefit, COT inhibitors may be combined with one or two other drugs that together will provide additional clinical benefit.

Abstract: Methods for determining various oncogenic-related indexes of patient specific mutations are provided. The methods provided allow determination and grading of various patient specific mutations and qualitative and quantitative determination of various related oncogenic indexes.

Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.

Abstract: Methods for identifying and determining drug response of patient specific oncogenic mutations are provided. The methods provided identify specific (personalized) drug treatment based on the effect of drug on the patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.

Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.

Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.

Abstract: Methods for identifying and determining drug response of patient specific oncogenic mutations are provided. The methods provided identify specific (personalized) drug treatment based on the effect of drug on the patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.

Abstract: Methods for determining various oncogenic-related indexes of patient specific mutations are provided. The methods provided allow determination and grading of various patient specific mutations and qualitative and quantitative determination of various related oncogenic indexes.

Abstract: Methods for identifying patient specific driver mutations are provided. The methods provided identify specific patient derived markers associated with aberrant signal transduction pathways, in biological samples of a cancer patient.

Abstract: The present invention provides a new approach for the treatment of G-protein coupled receptor based disease. This approach comprises altering the physiology of G-protein coupled receptor based responses by exerting chemical control over the cellular distribution of the receptor. This approach allows a method for phenotypic screening for candidate compounds which disrupt GPCR distribution signaling activity and are therefore candidates for the treatment of GPCR related conditions. Compounds that create an altered distribution of GPCR upon exposure to the cell are identified. The method then uses these molecules to alter physiology through their effect on receptor distribution and reduction to practice is demonstrated in an ex-vivo model of G-protein coupled receptor activity.